Autolus Therapeutics

$9.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.54 (-5.15%) Today
$0.00 (0.00%) As of 6:00 PM EST after-hours

Why Robinhood?

You can buy or sell AUTL and other stocks, options, and ETFs commission-free!

About AUTL

Autolus Therapeutics plc American Depositary Share, also called Autolus Therapeutics, is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. The listed name for AUTL is Autolus Therapeutics plc American Depositary Share.

CEO
Christian Martin Itin
Employees
292
Headquarters
London, Greater London
Founded
2018
Market Cap
520.37M
Price-Earnings Ratio
Dividend Yield
Average Volume
95.35K
High Today
$10.75
Low Today
$9.61
Open Price
$10.22
Volume
155.13K
52 Week High
$17.19
52 Week Low
$3.00

Collections

AUTL Earnings

-$0.93
-$0.62
-$0.31
-$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 2, Pre-Market

You May Also Like